Abstract:Real-world evidence (RWE) has an increasing role in preapproval settings to support the approval of new medicines and indications. The main objectives of this study were to identify and characterize regulatory use cases that utilized RWE and other related observational approaches through targeted review of publications and regulatory review documents. After screening and inclusion/exclusion, the review characterized 85 regulatory applications with RWE. A total of 31 were in oncology and 54 were in non-oncology therapeutic areas. Most were for indications in adults only (N = 42, 49.4%), while 13 were in pediatrics only (15.3%), and 30 were in both (35.3%). In terms of regulatory context, 59 cases (69.4%) were for an original marketing application, 24 (28.2%) were for label expansion, and 2 (2.4%) were for label modification. Most also received special regulatory designations (e.g., orphan indication, breakthrough therapy, fast track, conditional, and accelerated approvals). There were 42 cases that utilized RWE to support single-arm trials. External data to support single-arm trials were utilized in various ways across use cases, including direct matching, benchmarking, natural history studies as well as literature or previous trials. A variety of data sources were utilized, including electronic health records, claims, registries, site-based charts. Endpoints in oncology use cases commonly included overall survival, progression-free survival. In 13 use cases, RWE was not considered supportive/definitive in regulatory decision-making due to design issues (e.g., small sample size, selection bias, missing data). Overall, RWE is utilized in regulatory approval processes for new indications/label expansion across various therapeutic areas with wide range of approaches. Multifaceted cross-sector efforts are needed to further improve the quality and utility of RWE in regulatory decision-making.

Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes

Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment

Real-World Evidence: A Primer

Examining the Use of Real‐World Evidence in the Regulatory Process

The Use of Real-World Data/evidence in Regulatory Submissions.

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies

Utilization of real-world evidence in clinical research of medical devices

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

On the use of RWD in support of regulatory submission in drug development

Acceptability of using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps

Raising the Impact of Real World Evidence

Observational studies to emulate randomized trials: Some real‐world barriers

A comparative study of clinical trial and real-world data in patients with diabetic kidney disease